Alere→Abbott Laboratories
Acquisition · Cash + Stock · announced Feb 1, 2016
Announced
Feb 1, 2016
Closed
Oct 3, 2017
Economics
Cash + Stock()
Pre-deal · pre-deal mark: 2016, year precision · rounding grid ±$100M · Abbott 8-K filing, SEC EDGAR — Alere acquisition (NYSE:ALR market cap)
$51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
Target
Alere
Diagnostics · Diagnostic / genomic
HQ Waltham, MA · Founded 2001
Global leader in point-of-care diagnostics — rapid tests for cardiometabolic, infectious disease, and toxicology; includes pregnancy and fertility testing portfolio
- SEC EDGAR — Abbott/Alere amended merger filing (Apr 14, 2017)
- Abbott Mediaroom — merger amendment (Apr 14, 2017)
- Abbott Mediaroom — closing confirmation (Sep 29, 2017)
Acquirer
Abbott Laboratories
Healthcare
HQ Abbott Park, IL
Global healthcare company — diagnostics, medical devices, nutrition, pharmaceuticals; point-of-care testing leader via Alere acquisition
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Global leader in point-of-care diagnostics — $5.5B POC market includes rapid pregnancy, fertility, and women's health testing; expands Abbott's diagnostics presence in 100+ countries
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR — Abbott/Alere amended merger (Apr 14, 2017)
Tertiary (trade / analyst)
Abbott Mediaroom — closing (Sep 29, 2017)
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/1800/000110465916092968/a16-3252_18k.htm
Open source
Limitations
- $51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
- Pre-deal valuation sourced from: Abbott 8-K filing, SEC EDGAR — Alere acquisition (NYSE:ALR market cap). Pre-deal market-cap and funding citations do not corroborate the acquisition.
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| EUROIMMUN | PerkinElmer (Revvity) | Jun 16, 2017 | ||
| Counsyl | Myriad Genetics | May 28, 2018 | ||
| Sequenom | LabCorp | Jul 27, 2016 | ||
| nVision Medical | Boston Scientific | Apr 16, 2018 |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Alere (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.